Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 platform study of novel immunotherapy combinations in previously untreated PD-L1-high advanced or metastatic non-small-cell lung cancer
jRCT2051220100Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Dostarlimab + belrestotug, Dostarlimab + GSK6097608 and Pembrolizumab (3 arms). Primary endpoint: Objective response rate. Started Oct 2020; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051220100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220100.